Privia Health Group (NASDAQ:PRVA) Shares Gap Down – Should You Sell?
by Kim Johansen · The Markets DailyPrivia Health Group, Inc. (NASDAQ:PRVA – Get Free Report)’s stock price gapped down prior to trading on Thursday . The stock had previously closed at $23.96, but opened at $20.90. Privia Health Group shares last traded at $20.9930, with a volume of 401,384 shares traded.
Trending Headlines about Privia Health Group
Here are the key news stories impacting Privia Health Group this week:
- Positive Sentiment: Revenue exceeded expectations: Second-quarter revenue rose 21.4% year over year to $632.6 million, above the $597.3 million FactSet consensus. Six-month revenue reached $1.24 billion, up 23.5%. Privia Health second-quarter revenue results
- Positive Sentiment: Profitability and operating metrics improved: Net income attributable to Privia rose to $9.0 million from $2.7 million, while adjusted EBITDA increased 29.1% to $37.4 million. Implemented providers grew 10.1% to 5,644 and value-based-care attributed lives rose 19.2% to 1.647 million. Privia Health reports second-quarter results
- Positive Sentiment: Full-year outlook was raised: Management lifted 2026 guidance for attributed lives, practice collections, care margin, platform contribution and adjusted EBITDA. GAAP revenue is now expected at $2.35 billion to $2.45 billion, with the range’s upper end viewed favorably relative to the FactSet consensus of $2.42 billion. Privia Health 2026 revenue guidance
- Neutral Sentiment: EPS interpretation was mixed: Adjusted diluted EPS of $0.19 beat the $0.07 consensus cited by some outlets, but GAAP diluted EPS was $0.07 versus a Zacks estimate of $0.08. The quarter also included $19.4 million of non-cash stock compensation, limiting the quality of reported earnings. Privia Health earnings estimate report
- Negative Sentiment: Cash generation raised concerns: Privia used $48.4 million in operating cash during the first half, driven largely by a $172.4 million increase in accounts receivable. The company also reported continued insider selling, with no insider purchases among 31 reported transactions over six months.
Analyst Upgrades and Downgrades
A number of equities analysts recently issued reports on PRVA shares. Evercore set a $26.00 price objective on shares of Privia Health Group in a report on Wednesday, April 8th. Zacks Research cut Privia Health Group from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 7th. Canaccord Genuity Group cut their price target on Privia Health Group from $35.00 to $34.00 and set a “buy” rating for the company in a report on Friday, May 8th. Weiss Ratings raised Privia Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, July 2nd. Finally, Barclays reduced their target price on shares of Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating for the company in a report on Tuesday, May 26th. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Privia Health Group presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.15.
View Our Latest Stock Analysis on Privia Health Group
Privia Health Group Stock Down 11.9%
The stock’s 50 day moving average is $24.61 and its 200-day moving average is $23.36. The company has a market cap of $2.66 billion, a PE ratio of 131.77, a P/E/G ratio of 1.88 and a beta of 0.85.
Privia Health Group (NASDAQ:PRVA – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.07 by $0.12. Privia Health Group had a return on equity of 2.81% and a net margin of 0.97%.The company had revenue of $632.63 million during the quarter, compared to the consensus estimate of $597.33 million. During the same period last year, the company earned $0.24 earnings per share. Privia Health Group’s revenue was up 21.4% on a year-over-year basis. On average, analysts anticipate that Privia Health Group, Inc. will post 0.27 EPS for the current fiscal year.
Insider Transactions at Privia Health Group
In related news, CFO David Mountcastle sold 24,734 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $27.50, for a total value of $680,185.00. Following the transaction, the chief financial officer owned 186,728 shares of the company’s stock, valued at $5,135,020. This trade represents a 11.70% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew Shawn Morris sold 88,110 shares of Privia Health Group stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $25.33, for a total transaction of $2,231,826.30. Following the sale, the director owned 76,651 shares of the company’s stock, valued at $1,941,569.83. The trade was a 53.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 452,357 shares of company stock worth $11,436,655. Insiders own 5.70% of the company’s stock.
Institutional Investors Weigh In On Privia Health Group
Hedge funds have recently made changes to their positions in the company. ArrowMark Colorado Holdings LLC raised its position in shares of Privia Health Group by 139.4% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 841,266 shares of the company’s stock worth $19,946,000 after acquiring an additional 489,866 shares in the last quarter. Freestone Grove Partners LP boosted its position in Privia Health Group by 40.6% during the fourth quarter. Freestone Grove Partners LP now owns 1,213,342 shares of the company’s stock valued at $28,768,000 after purchasing an additional 350,194 shares in the last quarter. Renaissance Group LLC bought a new stake in Privia Health Group during the fourth quarter valued at about $7,776,000. Qube Research & Technologies Ltd grew its stake in Privia Health Group by 93.3% in the second quarter. Qube Research & Technologies Ltd now owns 609,278 shares of the company’s stock valued at $14,013,000 after purchasing an additional 294,101 shares during the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in Privia Health Group in the second quarter worth about $6,219,000. 94.48% of the stock is currently owned by hedge funds and other institutional investors.
Privia Health Group Company Profile
Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.
Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.